Monday, January 21, 2013

Bevacizumab QoL impact highlighted in ovarian cancer patients

The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life.

via Med Wire News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)